Prothena Corp Public (PRTA) Net Margin (2013 - 2026)
Prothena Corp Public (PRTA) recorded quarterly Net Margin of 64.05% in Q1 2026, up 100.06% quarter-over-quarter from 102804.76% in Q4 2025, and up 219259.0% on a YoY basis from N/an in Q1 2025.
Prothena Corp Public (PRTA) Net Margin (2013 - 2026) Analysis & Trends
Prothena Corp Public's Net Margin history runs 14 years deep, the most recent figure standing at 64.05% for Q1 2026.
- In Q1 2026, Net Margin rose 219259.0% year-over-year to 64.05%; the TTM figure through Mar 2026 stood at 260.87% (down 18088.0% YoY), while the FY2025 annual figure was 2520.57%, down 243008.0% from the prior year.
- Net Margin was 64.05% for Q1 2026 at Prothena Corp Public, up from 102804.76% in the prior quarter.
- In the past five years, Net Margin ranged from a high of 64.05% in Q1 2026 to a low of 144480.0% in Q1 2024.
- Historically, Net Margin has averaged 17447.51% across 5 years, with a median of 2731.09% in 2024.
- The sharpest annual moves came in 2024 and 2025: Net Margin tumbled 14231882 bps in 2024, then surged 14235146 bps in 2025.
- A 5-year view of Net Margin shows it stood at 12.72% in 2022, then plunged by 167978 bps to 21350.0% in 2023, then jumped by 87 bps to 2731.09% in 2024, then sank by 3664 bps to 102804.76% in 2025, then surged by 100 bps to 64.05% in 2026.
- The last three Net Margin figures came in at 64.05% (Q1 2026), 102804.76% (Q4 2025), and 1511.88% (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 0.82% |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 34.53% |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | Prothena Corp Public | 479.08 Mn | 149.61 Mn | - | 64.05% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 64.05% |
| Dec 31, 2025 | -102,804.76% |
| Sep 30, 2025 | -1,511.88% |
| Jun 30, 2025 | -2,845.41% |
| Mar 31, 2025 | -2,128.54% |
| Dec 31, 2024 | -2,731.09% |
| Sep 30, 2024 | -6,082.58% |
| Jun 30, 2024 | 50.64% |
| Mar 31, 2024 | -144,480.00% |
| Dec 31, 2023 | -21,350.00% |
| Sep 30, 2023 | 25.82% |
| Jun 30, 2023 | -1,358.57% |
| Mar 31, 2023 | -2,161.18% |
| Dec 31, 2022 | 12.72% |
| Sep 30, 2022 | -3,013.65% |
| Jun 30, 2022 | -3,145.73% |
| Mar 31, 2022 | -3,147.44% |
| Dec 31, 2021 | -2,830.97% |
| Sep 30, 2021 | 78.50% |
| Jun 30, 2021 | 45.94% |